Applications

The platform enables early identification of clinically relevant toxicities including hepatotoxicity, myelosuppression, and immune mediated adverse effects. Liver metabolism generates human specific metabolites that flow to downstream tissues, revealing compound liabilities before animal or clinical studies. This supports safer candidate selection and reduces late stage attrition.

By integrating immune components within a vascularised system, the technology supports evaluation of immune activation, cytokine signalling, and tumour immune interactions. This is critical for modern therapies where immune mediated effects often determine efficacy and risk.
The platform allows mechanistic investigation of immune responses that cannot be captured in isolated organ models.

The system supports modelling of complex diseases that involve multiple organs and circulating signals. Viral infection, inflammatory disorders, and systemic toxicities can be studied under controlled flow with real time measurement of coordinated tissue responses.
This enables hypothesis driven research and translational insight beyond endpoint screening.